CGZ-16042-01766
3 vaccinations
1 coded response
2 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 009 / PR
- Registered
- 2021-12-31
- Relationship
- Self
- Race
- N/A
- Ethnicity
- Hispanic or Latino
Timeline
-
2021-06-30
Dose 1 — Pfizer-BioNTech
-
2021-07-22
Dose 2 — Pfizer-BioNTech
-
2021-12-30
Dose 3 — Pfizer-BioNTech
-
2021-12-31
Registered in v-safe
-
2021-12-31
Survey response — days 1–6 daily, dose 3MedDRA: Headache, Vomiting — Feeling: Poor · Site: Pain, Redness · Fever · Headache, Joint pains, Muscle or body aches, Nausea, Vomiting, Abdominal pain · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: excessive vomiting and headacheMedDRA releases: 2024-11 · check-in free text available
-
2022-01-02
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Headache, Nausea · Be unable to do your normal daily activitiesAdult check-in
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-06-30 | Pfizer-BioNTech | No |
| 2 | 2021-07-22 | Pfizer-BioNTech | No |
| 3 | 2021-12-30 | Pfizer-BioNTech | No |
Free text
Release 10 — days 1–6 daily, dose 3
Systemic reaction (other): excessive vomiting and headache
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SRO | Headache | · | · | ✓ |
| SRO | Vomiting | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release